4//SEC Filing
Cohlhepp Ryan 4
Accession 0002034665-25-000004
CIK 0002023658other
Filed
Oct 7, 8:00 PM ET
Accepted
Oct 8, 5:33 PM ET
Size
17.2 KB
Accession
0002034665-25-000004
Insider Transaction Report
Form 4
Cohlhepp Ryan
DirectorPresident and COO
Transactions
- Sale
Common Stock
2025-10-07$18.06/sh−8,000$144,473→ 205,541 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-07−8,000→ 165,334 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (8,000 underlying) - Exercise/Conversion
Common Stock
2025-10-07$3.79/sh+8,000$30,318→ 213,541 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-06−24,000→ 173,334 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (24,000 underlying) - Sale
Common Stock
2025-10-06$18.06/sh−15,600$281,666→ 205,541 total - Sale
Common Stock
2025-10-07$18.06/sh−2,900$52,371→ 202,641 total - Sale
Common Stock
2025-10-06$18.06/sh−24,000$433,332→ 221,141 total - Exercise/Conversion
Common Stock
2025-10-06$3.79/sh+24,000$90,955→ 245,141 total
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F4]The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.
Documents
Issuer
Bicara Therapeutics Inc.
CIK 0002023658
Entity typeother
Related Parties
1- filerCIK 0002034665
Filing Metadata
- Form type
- 4
- Filed
- Oct 7, 8:00 PM ET
- Accepted
- Oct 8, 5:33 PM ET
- Size
- 17.2 KB